Bundle (CJC-1295 No Dac 2mg x5 + Ipamorelin 2mg x5)

This bundle pairs five individually-supplied vials of CJC-1295 NO-DAC (2mg) with five individually-supplied vials of Ipamorelin (2mg), spanning a considerable size range from a 29-residue GRF analog down to a 5-residue secretagogue.

Stabilization Without Albumin Conjugation

Unlike the DAC-conjugated variant of this same GRF analog, CJC-1295 NO-DAC relies solely on four internal sequence substitutions, D-alanine, glutamine, alanine, and leucine at specific positions, to resist enzymatic and chemical degradation, without any added albumin-binding extension.

This keeps the peptide closer in overall structure to native GRF(1-29) while still addressing the same degradation pathways that limit the unmodified hormone's stability in laboratory use.

GHRH Receptor Engagement

Structural and computational research has characterized the dynamic properties of the GHRH receptor and the molecular determinants of GHRH binding, offering a receptor-level basis for how CJC-1295 NO-DAC's retained GHRH-derived sequence is positioned to engage this receptor in laboratory studies.¹

A Five-Residue Counterpart on the Other Receptor

Where CJC-1295 NO-DAC is a near full-length hormone analog, Ipamorelin is built from just five residues and engages an entirely separate target, the growth hormone secretagogue receptor (GHS-R), the same receptor activated naturally by ghrelin.

Its Aib residue, a non-proteinogenic amino acid with a quaternary carbon that restricts backbone rotation, is studied for its contribution to both binding conformation and resistance to exopeptidase degradation despite the peptide's short length.

Combined Research Applications

Because these two peptides differ so substantially in size and target receptor, this bundle is suited to research examining GHRH-receptor and GHS-R pathways side by side within a single experimental platform.

Interaction effects between the two when studied together remain an open question in the literature, with available data still preliminary.

Analytical Verification Across Two Very Different Peptides

The nearly six-fold size difference between these two peptides means researchers should expect distinct analytical profiles: CJC-1295 NO-DAC's longer sequence is more prone to deletion-sequence byproducts during synthesis, while Ipamorelin's short length makes truncation products easier to resolve by mass alone.

Certificates of analysis for each compound should be reviewed independently rather than assumed to carry over from one peptide to the other.

Storage and Handling in the Laboratory Setting

Both peptides are kept lyophilized under sub-zero freezer conditions until shortly before use, since peptide bonds in either compound become more susceptible to hydrolysis once removed from this stable, freeze-dried state.

Important Notice

CJC-1295 NO-DAC and Ipamorelin are strictly for in vitro laboratory research purposes only and are not intended for human consumption. These findings do not establish safety, efficacy, or suitability for any human application, and these products have not been evaluated by the FDA or any regulatory agency.

Product Information

This bundle includes 5 vials of CJC-1295 NO-DAC at 2mg per vial and 5 vials of Ipamorelin at 2mg per vial, supplied as lyophilized powders for laboratory research use only.

References

1. Matsoukas MT, Spyroulias GA. Dynamic properties of the growth hormone-releasing hormone receptor (GHRHR) and molecular determinants of GHRH binding. Mol Biosyst. 2017;13(7):1313-1322.